31 results about "Renal glomerulus" patented technology

The invention discloses a glomerular segmentation method based on multi-scale Mama and dynamic sampling, and relates to the technical field of medical images. According to the method, the input multi-scale features are efficiently represented by using a continuous state transition mechanism, the structural association information extraction capability among different scales is enhanced, in addition, the problem of geometric distortion in dynamic sampling is solved by introducing position coding into the dynamic sampling method and adding position constraint information, and the dynamic sampling efficiency is improved based on a U-Net model. An MS-Mama module is gradually added in the encoder stage, and an existing bilinear interpolation method is replaced by a position sensing dynamic sampling module; and then, serialized representation is performed on multi-scale features based on a selective state space mechanism, the dependence of Mama on specific scale features is reduced, the ability of extracting heterogeneous morphological features of lesion glomerulus is enhanced, the boundary positioning precision of lesion glomerulus is enhanced by adding position constraint information, and the geometric distortion problem in dynamic sampling is solved.

The invention relates to a deep learning-based early-stage amyloidosis nephropathy identification and diagnosis method, belongs to the technical field of amyloidosis nephropathy identification, and solves the problem that early-stage amyloidosis cannot be accurately identified in the prior art. The method comprises the following steps: acquiring kidney pathological section images of different individuals to construct a training sample set; constructing a link model comprising a first region segmentation model, a second region segmentation model and a third region segmentation model; the first region segmentation model is used for segmenting a cortex region in the pathological image; the second region segmentation model is used for segmenting a glomerular region; the third region segmentation model is used for identifying amyloidosis of a glomerular region; training the link model based on the training sample set to obtain a trained link model; and inputting a to-be-identified kidney pathological section image into the trained link model to identify whether amyloidosis exists or not. And efficient and accurate early-stage amyloidosis identification is realized.

Described herein are fusion proteins which include factor H functional domains and may include VHH domains and integrin binding domains, and the use of such fusion proteins in methods of treatment of focal segmental glomerulosclerosis.

A system and method for diagnosing a patient's renal function, the method comprising delivering a first tracer agent, transmucosally applying a first excitation light to the first tracer agent at the first monitoring site, transmucosally receiving a first fluorescent light emitted from the first tracer agent at the first monitoring site, transforming the received first fluorescent light to produce a first fluorescence signal, processing the first fluorescence signal to determine a first decay rate, and processing the first decay rate of the first fluorescent light to determine a glomerular filtration rate of the patient.

The application discloses a biomarker for diagnosing diabetic nephropathy and application thereof, and relates to the technical field of biological medicine. The biomarker for diagnosing diabetic nephropathy comprises urine MBP-1 or urine MBP-1 / urine creatinine. The urine MBP-1 or urine MBP-1 / urine creatinine biomarker has high identification efficiency: when the urine MBP-1 or urine MBP-1 / urine creatinine ratio is used for identifying DKD and NDRD, the area under the ROC curve (AUC) reaches 0.899, the sensitivity and the specificity are both higher than 0.85, and the two diseases can be efficiently distinguished. The method is non-invasive and convenient: only urine samples need to be collected, the risk of complications such as bleeding and infection caused by invasive operations such as kidney biopsy is avoided, the patient has high acceptance, repeated detection can be performed to dynamically track the disease condition, and special equipment is not needed, so that the method is convenient for clinical popularization and application. Through kidney tissue immunofluorescence verification, MBP-1 is deposited in a large amount in the glomerulus of DKD and is not deposited in NDRD, and thus the kidney local pathological change can be directly reflected.

This invention belongs to the field of renal pathology testing technology and discloses a method for detecting type IV collagen expression in renal biopsy tissue, comprising the following steps: dewaxing and hydrating paraffin sections of renal biopsy tissue to obtain processed tissue sections; adding the processed tissue sections to a repair solution, heating to boiling, and then cooling to room temperature to obtain repaired tissue sections; adding protease to the repaired tissue sections for enzymatic digestion to obtain enzymatically digested tissue sections; adding a primary antibody to the enzymatically digested tissue sections for preliminary incubation, followed by adding a fluorescein-labeled secondary antibody against the primary antibody for further incubation. This method for detecting type IV collagen expression in renal biopsy tissue is applicable to cases where renal biopsy tissue lacks glomeruli or has too few glomeruli to detect type IV collagen expression. It has high specificity and can provide a new detection method for Alport syndrome in cases where renal biopsy tissue lacks glomeruli.

The invention relates to the fields of therapy and drug delivery. It is based on an unexpected finding that a combination of an oligonucleotide-based medicament with a saponin component comprising a penta-cyclic triterpene saponin of a 12,13-dehydrooleanane aglycone core, not only does not appear to be associated with oligonucleotide medicament-induced nephrotoxic effects after systemic administration in vivo, but also that it allows the oligonucleotide-based medicament to enter and act on its nucleic acid target inside of the kidney cells instead of remaining unproductively trapped in renal subcellular compartments or being eliminated into the urine via the renal glomerular filtration system. In line with this finding, herein disclosed are therapeutic combinations, compositions, and formulations, as well as methods of treatment involving their administration, which comprise an oligonucleotide-based medicament that acts on an intracellular nucleic acid target in the kidney cells and / or in the cells of the spleen, being the other blood filtering organ in addition to the kidney, and a saponin component that enables the effective release of said medicament inside of these cells, thus allowing its use at a much lower and safer dose. The provision of the presented herein therapeutic combinations enables effective modulation of gene expression in the kidney and / or spleen cells and, therefore, it opens not only new treatment options for kidney diseases, in particular those involving inflammation and / or splenomegaly, but also for diseases of other organs which affect or are affected by the pathological processes happening in the kidneys and / or in the spleen, in particular being inflammatory processes.

The invention provides a traditional Chinese medicine preparation for treating type 2 diabetic nephropathy and a preparation method and application thereof, and relates to the technical field of traditional Chinese medicine. The traditional Chinese medicine reagent is characterized by comprising the following raw materials: astragalus membranaceus, prepared rehmannia root, dogwood, salvia miltiorrhiza, safflower, poria cocos, rhizoma alismatis, prepared rhubarb, codonopsis pilosula and winged euonymus twig. The traditional Chinese medicine composition has the effects of tonifying qi, activating blood, tonifying kidney and removing turbidity through cooperation of the medicines. The whole formula focuses on the pathogenesis of deficiency stasis and turbid toxin, and the treatment effect is achieved through multiple target points and multi-layer effects. Animal experiments show that the preparation can significantly relieve glomerular mesangial matrix hyperplasia and renal interstitial fibrosis. Clinical experiments show that traditional Chinese medicine symptom scores and curative effects are reduced, blood sugar is controlled, and laboratory indexes related to renal functions are improved.

The application discloses a foot process identification method and device for electron microscope images of chronic kidney disease and terminal equipment, obtains the electron microscope pathological images of chronic kidney disease with labeled foot process position characteristics, and trains a preset deep network architecture through the electron microscope pathological images of chronic kidney disease to obtain a foot process identification model, so that when the electron microscope images of chronic kidney disease to be detected are obtained, the automatic identification of the foot process area corresponding to the electron microscope images to be detected can be realized through the obtained foot process identification model, and the automatic identification of the foot process area of the electron microscope images of chronic kidney disease is realized. The application accurately and quickly identifies the area corresponding to the foot process through the deep learning mode, improves the foot process identification efficiency of the electron microscope images of chronic kidney disease, is favorable to improving the pathological diagnosis and analysis efficiency of various types of glomerulonephritis for pathologists, and can reduce misdiagnosis and missed diagnosis caused by insufficient experience.

A low-salt fasting-mimicking diet (LS-FMD) is provided for promoting kidney regeneration and treating kidney disease. The LS-FMD comprises cyclic dietary interventions that reduce caloric and sodium intake to induce fasting-like metabolic effects while maintaining essential nutrition. In animal models of puromycin-induced nephrosis, LS-FMD cycles restore normal proteinuria levels and improve nephron structure and function relative to untreated controls. The diet activates kidney-specific gene expression programs and promotes a quiescent, non-proliferative state in mature podocytes, supporting renal recovery. In human subjects with chronic kidney disease, administration of fasting-mimicking diet cycles for five days per month over three months reduces proteinuria and improves endothelial function. The invention demonstrates that kidney-specific fasting-mimicking dietary cycles have therapeutic potential for slowing or reversing progressive renal disorders.

This invention discloses an engineered extracellular vesicle and its application in the preparation of products for treating autoimmune diseases. The engineered extracellular vesicle is either an IDO1-overexpressing engineered extracellular vesicle (MSC-IDO1-EVs) or a CSF1-overexpressing engineered extracellular vesicle (MSC-CSF1-EVs). The engineered extracellular vesicles provided by this invention exhibit significant immunosuppressive effects, reducing the secretion of inflammatory cytokines. In animal models, they effectively reduce proteinuria levels, significantly reduce blood dsDNA / ANA levels, effectively alleviate kidney damage caused by autoimmune diseases such as renal immune complex deposition, diffuse thickening of the glomerular basement membrane, and mesangial structural disorder, and reduce overall inflammation levels in mice. The therapeutic effect is significantly superior to that of unmodified MSC-EVs. The engineered extracellular vesicles provided by this invention significantly improve the therapeutic effect on autoimmune diseases.

The invention relates to the technical field of biological medicine, in particular to a composition for reducing the occurrence rate of renal edema and improving the glomerular filtration function and application. The composition comprises the following active ingredients: pseudo-ginseng, American ginseng powder and algal polysaccharides, and the active ingredients are crushed, sieved and uniformly mixed to prepare different dosage forms. The composition has remarkable and excellent effects on reducing the occurrence rate of renal edema and improving the glomerular filtration function, and compared with products in the prior art, the composition has the advantage that the use cost of raw materials is reduced.

The present invention relates to a method for measuring glomerular filtration rate (GFR) ex vivo in a subject that has been administered a contrast agent and that has been subjected to computed tomography (CT) or magnetic resonance imaging (MRI) including an excretion phase, a plain scan phase, an arterial phase, and a renal parenchyma phase or a portal vein phase, the method includes the step of calculating contrast agent clearance from CT or MRI data using manual, automated or semi-automated segmentation software, thereby obtaining a measured GFR.

The application provides a preparation method of total saponins of Radix Fritillariae Thunbergii, which comprises the following steps: adding Radix Fritillariae Thunbergii into ethanol to extract, and then concentrating under reduced pressure to obtain a crude extract; dissolving the crude extract in water, and then adsorbing the water on macroporous adsorption resin, and then eluting the macroporous adsorption resin with water and ethanol; collecting the ethanol eluate, and then concentrating under reduced pressure to obtain component 1; dissolving the component 1 in water, and then extracting with an organic solvent; and drying the water phase obtained by extraction under reduced pressure to obtain the total saponins of Radix Fritillariae Thunbergii. The application optimizes the extraction and purification method of the total saponins of Radix Fritillariae Thunbergii to a certain extent, shortens the preparation time of the total saponins, improves the content of the total saponins, and proves through experimental research that the total saponins of Radix Fritillariae Thunbergii can treat the nephrotic syndrome caused by adriamycin (ADR), improve the glomerular filtration rate, reduce the glomerular inflammation, and has a significant protective effect on the kidney.

The application belongs to the technical field of disease drug treatment, and particularly relates to application of a CLK2 inhibitor in preparation of a drug for treating IgA nephropathy. The CLK2 inhibitor (such as ganoderic acid A methyl ester) can significantly reduce 24hUTP, 24hmAlb, BUN and Scr levels of an IgA nephropathy model, and IGA deposition in the inside of a glomerulus, so as to achieve the purpose of effectively treating IgA nephropathy.

Provided are oligonucleotides, polynucleotide conjugates, and compositions and populations comprising the same, as well as methods and uses thereof for reducing the amount or activity of Rho guanine nucleotide exchange factor 6 (ARHGEF6) RNA in a cell or animal, and in certain instances reducing the amount of ARHGEF6 protein in a cell or animal Such oligonucleotides, polynucleotide conjugates, and compositions and populations, methods and uses are useful to treat kidney diseases or conditions. In particular, such oligonucleotides, polynucleotide conjugates, and compositions and populations, methods and uses are useful to treat chronic kidney disease, such as diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS), renal hypertension (HTN), IgA nephropathy / Berger's disease (IgAN), rapidly progressive glomerulonephritis (RPGN) and systemic lupus erythematosus (SLE).

The invention relates to the fields of therapy and drug delivery. It is based on an unexpected finding that a combination of an oligonucleotide-based medicament with a saponin component comprising a penta-cyclic triterpene saponin of a 12,13-dehydrooleanane aglycone core, not only does not appear to be associated with oligonucleotide medicament-induced nephrotoxic effects after systemic administration in vivo, but also that it allows the oligonucleotide-based medicament to enter and act on its nucleic acid target inside of the kidney cells instead of remaining unproductively trapped in renal subcellular compartments or being eliminated into the urine via the renal glomerular filtration system. In line with this finding, herein disclosed are therapeutic combinations, compositions, and formulations, as well as methods of treatment involving their administration, which comprise an oligonucleotide-based medicament that acts on an intracellular nucleic acid target in the kidney cells, and a saponin component that enables the effective release of said medicament inside of the kidney cells, thus allowing its use at a much lower and safer dose. The provision of the presented herein therapeutic combinations enables effective modulation of gene expression in the kidney cells and, therefore, it opens not only new treatment options for kidney diseases, but also for diseases of other organs which affect the kidneys and / or which are affected by inefficient or impaired kidney function.

The invention relates to the technical field of medical data processing, in particular to a kidney macrophage iron steady state regulation and control method and system and a storage medium. Comprising the following steps: acquiring iron metabolism data of macrophages in a disease environment from a biological database, and analyzing aging characteristics of an enzyme system to obtain an enzyme system function weakening index; evaluating an iron accumulation level in the glomerular injury sample, calculating an iron accumulation risk value, and constructing a risk distribution model; grouping iron accumulation risks through a clustering algorithm, extracting iron transfer parameters, and dividing sample differences to obtain an iron removal efficiency change trend; performing metabolism intervention according to the change trend, optimizing an iron metabolism path, simulating a cell steady-state index, and evaluating the regulation capability; the regulation capability and renal injury data are integrated, the protection contribution of iron ion removal to kidney cells is evaluated, and a protection mechanism is disclosed. The kidney macrophage iron steady state regulation and control method solves the problem of kidney macrophage iron steady state regulation and control and realizes accurate intervention on iron metabolism, so that kidney cells are effectively protected.

The present disclosure relates to RNAi agents, such as double-stranded RNAi agents or siRNAs, that can inhibit expression of the complement component C3 (C3) gene. Also disclosed are pharmaceutical compositions containing the C3 RNAi agents and methods of using them. The C3 RNAi agents disclosed herein can be conjugated to targeting ligands, including N-acetylgalactosamine-containing ligands, to facilitate delivery to liver cells. Delivery of the C3 RNAi agents in vivo provides inhibition of C3 gene expression. The RNAi agents can be used in methods for treating diseases, disorders, or conditions mediated in part by C3 gene expression, including IgA nephropathy, C3 glomerulopathy, paroxysmal nocturnal hemoglobinuria, and / or other complement-mediated kidney diseases.

The application provides a kind of prediction method and model of early renal function decline risk of renal cell carcinoma patient after partial nephrectomy.Methods obtain patient clinical parameters by preoperative nomogram or preoperative-intraoperative joint nomogram prediction model, assign each parameter risk score and calculate total score, determine the prediction probability of early postoperative renal function decline and can be visualized output.Preoperative nomogram prediction model parameters include age, history of diabetes, preoperative estimated glomerular filtration rate, kidney score and radiomics score;Intraoperative ischemia time is added to the joint model.Model construction is standardized by CT image, region segmentation, radiology feature extraction and preprocessing, etc., which can assist clinical precise risk assessment and optimize treatment decision.

To provide an ATP production promoter useful for preventing or treating diseases associated with decreased ATP production, particularly renal impairment. [Solution] The present invention comprises an ATP production promoter containing a component having URAT1 inhibitory activity. Preferably, the component having URAT1 inhibitory activity is at least one selected from the group consisting of benzbromarone, probenecid, dotinurad, recinurad, and berinurad. The present invention is expected to be useful as a preventive and therapeutic agent for diseases of decreased ATP production, and is particularly useful as a therapeutic and / or preventive agent for nephrotic syndrome, chronic glomerulonephritis, chronic tubulointerstitial nephritis, chronic pyelonephritis, amyloid kidney, familial juvenile hyperuricemia nephropathy, autosomal dominant tubulointerstitial kidney disease, nephronoplasia, renovascular hypertension, renal vein thrombosis, renal arteriovenous fistula, renal tubular acidosis, Gitelman syndrome, Bartter syndrome, Fanconi syndrome, Lowe syndrome, Alport syndrome, kidney and ureteral stones, and chronic renal failure.

The application provides a binding protein specifically binding to glomerular basement membrane, a preparation method and application, and relates to the technical field of biotechnology. The binding protein contains a heavy chain variable region and a light chain variable region, the complementarity determining region of the heavy chain variable region includes an amino acid sequence identical to VH-CDR1, VH-CDR2 and VH-CDR3 of the heavy chain variable region shown in SEQ ID NO. 1; the complementarity determining region of the light chain variable region includes an amino acid sequence identical to VL-CDR1, VL-CDR2 and VL-CDR3 of the light chain variable region shown in SEQ ID NO. 2. The binding protein has good specific binding capacity to the glomerular basement membrane antigen, and can be used for identification of anti-glomerular basement membrane antibodies or glomerular basement membrane antigens, and diagnosis and detection of anti-glomerular basement membrane antibody positive diseases and / or vasculitis.

Use of a traditional Chinese medicine in preparing a drug for preventing and treating nephritis. The traditional Chinese medicine is prepared from Taraxacum officinale, Polygonum cuspidatum, Sonchus oleroceus L., and Herba Scutellariae barbatae. Danio rerio is adopted for modeling. Animal experiments prove that the traditional Chinese medicine can be used for treating nephritis caused by aristolochic acid, protecting kidney functions and / or ameliorating renal dysfunction edema, and specifically, promoting glomerular filtration. 

To provide new agents capable of inhibiting the progression of chronic kidney disease.SOLUTION: A chronic kidney disease progression inhibitor is prepared that includes dantrolene or a pharmaceutically acceptable salt thereof, or a hydrate of them as an active ingredient. Preferably, the inhibitor is applied to chronic kidney disease involving proteinuria and / or glomerulosclerosis and is administered to a patient who has undergone kidney removal or a patient after renal infarction.SELECTED DRAWING: Figure 2

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a preparation method of purified poria cocos polysaccharide with kidney protection activity. The preparation method comprises the following steps: adding water into poria cocos, performing ultrasonic treatment, and performing suction filtration to obtain supernate 1 and precipitate; adding water, beta-glucanase and cellulase into the precipitate, performing enzymolysis, and performing suction filtration to obtain supernate 2; and finally, mixing the supernate 1 and the supernate 2 to obtain the poria cocos extracting solution. Compared with a water extraction process, the process disclosed by the invention has the advantages that the polysaccharide molecular weight can be effectively reduced, the antioxidant activity is improved, the purified poria cocos polysaccharide FL-1 is obtained through deproteinization and sephadex column chromatography separation and purification, and the purified poria cocos polysaccharide FL-1 is evaluated through a renal tubular epithelial cell aging model and a zebra fish kidney injury model. The cell activity can be obviously improved, the content of beta-galactosidase is reduced, and the content of NAD < + > is improved; the occurrence rate of the renal edema of the zebra fish can be obviously reduced, and the glomerular filtration function of the zebra fish is improved.

One aspect of the present disclosure provides an antigen-binding molecule comprising a dimeric Fc region and an antigen-binding domain, wherein: either or both of a first polypeptide chain comprising one monomer of the Fc region and a second polypeptide chain comprising another monomer of the Fc region do not include an antibody hinge region capable of forming a disulfide bond; and the antigen-binding domain is linked only to the first polypeptide chain, and the antigen-binding domain is not linked to the second polypeptide chain. Antigen binding molecules of this format have high glomerular permeability and can accumulate in the kidney.

The use of traditional Chinese medicine in the manufacture of drugs to prevent and treat nephritis. This traditional Chinese medicine is made from Taraxacum officinale, Polygonum cuspidatum, Sonchus oleroseus L., and Scutellariae barbatae Herba. Danio rerio fish was adopted as a model. Animal experiments have proven that traditional Chinese medicine can help. It is used to treat nephritis caused by aristolochic acid, protect kidney function and / or reduce edema in renal dysfunction, and specifically, increase glomerular filtration.

A method of estimating glomerular filtration rate of a feline can include measuring a blood sample of a feline for blood serum concentrations of pseudouridine and acetylthreonine, and optionally phenylacetylglutamine, and / or tryptophan, and also calculating a blood serum level product. The method can also include applying a feline factor as a multiple to the blood serum level product resulting in an estimated glomerular filtration rate. Calculating the blood serum level product can be based on a first weighted value based upon the blood serum concentration of pseudouridine, a second weighted value based upon the blood serum concentration of acetylthreonine,, an optional third weighted value based upon the blood serum concentration of phenylacetylglutamine, and an optional fourth weighted value based upon the blood serum concentration of tryptophan.

This invention discloses a myelin-inspired three-dimensional PEG-modified tetrahedral framework nucleic acid and its application in achieving long circulation and rapid renal clearance. Using a DNA tetrahedral framework as a programmable backbone, PEG units are periodically introduced onto each edge of the DNA tetrahedron. The PEG chains are used as active structural components rather than passive surface modifiers to construct a myelin-inspired three-dimensional topological PEG network coating structure. Without significantly increasing the size of small molecules, a dense steric barrier is formed, significantly reducing serum protein adsorption and nuclease degradation. Simultaneously, it efficiently crosses the glomerular filtration barrier, achieving a synergistic effect in mice with approximately a two-fold increase in blood circulation half-life and over 90% renal clearance within 4 hours. Furthermore, it exhibits good biocompatibility and in vivo safety, providing a novel, efficient, and safe nucleic acid drug delivery strategy for diseases related to the accumulation of target substances, such as hyperbiliary acidosis.

Methods for treating systemic lupus erythematosus using compounds or pharmaceutical compositions that modulate the activity of Bcl-2 family proteins are disclosed. In some methods, the patient to be treated is diagnosed with lupus nephritis. In some methods, the compound or pharmaceutical composition is administered to the patient in need thereof at a therapeutically effective dose sufficient to elicit one or more effects selected from: reduced excretion of protein in the urine of the patient, reduced serum anti-dsDNA autoantibody levels in the patient, reduced skin lesion severity in the patient, reduced lymphadenopathy severity in the patient, reduced glomerulonephritis severity in the patient, reduced vasculitis severity in the patient, reduced lymphocyte cell counts in a peripheral blood mononuclear cell (PMBC) panel taken from the patient, reduced lymphocyte cell counts in the spleen of the patient, and reduced lymphocyte infiltration of the kidneys of the patient.